The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, would like to provide an ...

Dynavax’s adult hepatitis B vaccine HEPLISAV-B is currently marketed in the US and is differentiated by its two-dose regimen over one month, which enables high levels of seroprotection faster than ...

Paris, December 24, 2025. The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the new drug application of tolebrutinib to treat non-relapsing secondary ...

Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Andrew Levin, M.D., Ph.D., ...

Harvard-trained orthodontist offers complimentary 15-minute airway analysis to help identify hidden causes of childhood focus problems. LOS ANGELES, Dec. 23, 2025 (GLOBE NEWSWIRE) ...

“Andrew’s extensive capital markets and in-house finance experience make him a strong addition to the Pelthos Board of Directors,” said Peter Greenleaf, Chairman of the Board. “His experience ...

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, announced ...

LA JOLLA, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Singlera Genomics, a company focused on the development and application of novel DNA methylation technologies to genetic diagnosis, today announced ...

ICP-488 is an oral, potent, and selective TYK2 allosteric inhibitor. By binding to the JH2 domain, ICP-488 blocks the signal transduction of IL-23, IL-12, type 1 IFN, and other inflammatory cytokines, ...

LAPIX Therapeutics, Inc. (“LAPIX”), a clinical-stage biopharmaceutical company developing first-in-class, orally delivered immune-tolerance-restoring therapies, announced today that the first patient ...

The securities issued and issuable, described in this and the previous news release on November 6, 2025, will be subject to a statutory hold period of four months plus a day from the date of issuance ...

We are excited to share updated overall survival data from our ongoing Phase 2a trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients,” said Ben Zeskind, Ph.D., ...